drugset / Trial / NCT06593522
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
RandomizedSequentialOpen-labelTreatment
Summary
The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
Timeline
- Start
- 2024-12-26
- Primary completion
- 2026-10-31
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anvumetostat | Unknown | — | Oral |
Indications
No indication recorded.